新加八味降酶湯聯(lián)合異甘草酸鎂治療藥物性肝損傷臨床療效觀察
[Abstract]:Objective: to observe the TCM syndromes scores, symptoms of discomfort and serum biochemical indexes, B-ultrasound scores, and so on, in the treatment of drug-induced liver injury (drug-included liver injury,DILI) by the combination of Xinjiawei Jiangxintang and magnesium isoglycyrrhizinate (magnesium isoglycyrrhizinate,MgIG). In order to provide a new therapeutic scheme for DILI, the therapeutic effect of traditional Chinese medicine combined with magnesium isoglycyrrhizinate was observed, and the therapeutic effect, advantages and disadvantages of the combination of traditional Chinese medicine and magnesium isoglycyrrhizinate were discussed in order to provide a new therapeutic scheme for clinical treatment of DILI. Methods: all the cases were selected from September 2015 to December 2016 in the Department of infection of Jiangsu Provincial Hospital of traditional Chinese Medicine (DILI). Sixty patients with DILI were randomly divided into two groups: treatment group (n = 30) and control group (n = 30). The control group was treated with magnesium isoglycyrrhizinate, and the treatment group was treated for 6 weeks. To observe and record the changes of liver function, symptoms of discomfort and B-ultrasound score before and after treatment, and to analyze the curative effect. The changes of blood, urine, fecal routine, electrocardiogram and renal function were observed before and after treatment. Results: (1) after 3 weeks of treatment, 30 cases were clinically effective, 0 cases were ineffective and 100 cases were effective in the treatment group, while 15 cases were effective, 15 cases were ineffective, and the effective rate was 50 cases in the control group. In the treatment group, 1 case was clinically cured, 27 cases were effective, 2 cases were effective, 0 cases were ineffective, and the total effective rate was 100 cases in the treatment group, while in the control group, 5 cases were clinically effective, 23 cases were effective, 2 cases were ineffective, and the total effective rate was 50%. There was significant difference in the total curative effect between the two groups (P0.01). (2). There was significant difference in TCM syndromes score between the two groups after 3 weeks and 6 weeks of treatment (P0. 01). After treatment, the symptom scores of the treatment group and the control group were significantly lower than those of the control group before treatment, and the difference was statistically significant (P0.01). (3) serological index: comparison between groups: at 3 weeks after treatment, AST,AKP, GGT had statistical difference (P0.05) and ALT,TB had significant difference (P0.01). At 6 weeks, there was no statistical difference between the two groups (P = 0.05). Analysis of each item in the group: treatment group: at 3 weeks, 6 weeks after treatment, the indexes were significantly different from those before treatment (P0.01); There was no significant difference in AST (P0. 737) and significant difference in ALT,AKP,GGT,TB (P0. 01) between week 6 and week 3. In the control group, the two indexes of AST,ALT were significantly different from those of before treatment at 3 weeks (P0.01), but AKP,GGT,TB had no significant difference (P0.01). At 6 weeks after treatment, there was significant statistical difference between the indexes before treatment (P0.01) and between the 6th week and 3rd week (P0.05). There was no significant difference in B-ultrasound score between the two groups at 6 weeks after treatment (P0.05). Compared with before treatment, the B-ultrasound score at 3 weeks and 6 weeks decreased significantly (P0.05). There were no significant adverse reactions in the two groups, blood, urine, fecal routine, electrocardiogram (ECG), blood, urine, stool routine, electrocardiogram (ECG), blood, urine, stool routine, electrocardiogram (ECG). The renal function were all abnormal changes related to this drug. Conclusion: the treatment of DILI, with new eight kinds of Jiangxin decoction combined with magnesium isoglycyrrhizinate is superior to that of magnesium isoglycyrrhizinate alone in improving the symptoms and signs and liver function of the patients, and has good safety.
【學(xué)位授予單位】：南京中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R575
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 賀露露;陳飛;;異甘草酸鎂治療68例慢性重度乙型肝炎體會(huì)[J];當(dāng)代醫(yī)學(xué);2013年26期
2 劉瑩;李展翼;胡成;鄭玉寶;高志良;;單用異甘草酸鎂與聯(lián)合激素治療慢性乙型重型肝炎的療效對(duì)比[J];熱帶醫(yī)學(xué)雜志;2013年09期
3 李肖玲;孫黎;沈金芳;陸倫根;曹愛萍;曹惠明;;異甘草酸鎂注射液正常人體耐受性試驗(yàn)[J];中國藥房;2006年04期
4 李異;蔣永芳;;異甘草酸鎂治療急性藥物性肝損傷的療效觀察[J];中西醫(yī)結(jié)合肝病雜志;2007年05期
5 莊開贊;王幼萍;;異甘草酸鎂聯(lián)合茵梔黃治療慢性乙型病毒性肝炎40例[J];中國藥業(yè);2009年07期
6 龍素軍;彭忠田;劉映霞;李佳;王培;;異甘草酸鎂對(duì)大鼠肝星狀細(xì)胞增殖和活力的影響[J];中國實(shí)用醫(yī)藥;2010年11期
7 陳愛東;陳東麟;;異甘草酸鎂聯(lián)合復(fù)方二氯醋酸二異丙胺治療非酒精性脂肪性肝炎療效觀察[J];牡丹江醫(yī)學(xué)院學(xué)報(bào);2010年03期
8 王湛;王杰軍;;異甘草酸鎂治療化療后肝功能異常60例臨床觀察[J];海南醫(yī)學(xué)院學(xué)報(bào);2010年07期
9 趙艷娟;楊梓梅;;異甘草酸鎂治療慢性重型乙型肝炎的臨床療效觀察[J];臨床肝膽病雜志;2010年05期
10 桂亞萍;;異甘草酸鎂治療慢性乙型肝炎療效觀察[J];中國醫(yī)藥指南;2010年36期
相關(guān)會(huì)議論文 前10條
1 周建芳;;異甘草酸鎂聯(lián)合苦黃治療病毒性肝炎高膽紅素血癥38例[A];第十次浙江省中西醫(yī)結(jié)合肝病學(xué)術(shù)會(huì)議論文匯編[C];2008年
2 湯麗娜;姚陽;;異甘草酸鎂治療抗腫瘤藥物引起的急性藥物性肝損傷的Ⅲ期臨床研究[A];第八屆全國癌癥康復(fù)與姑息醫(yī)學(xué)大會(huì)論文匯編[C];2012年
3 余輝;;異甘草酸鎂治療慢性乙肝的臨床觀察[A];第二屆全國病毒性肝炎慢性化重癥化基礎(chǔ)與臨床研究進(jìn)展學(xué)術(shù)會(huì)議論文匯編[C];2012年
4 孟繁平;李捍衛(wèi);趙平;金波;向軼;;異甘草酸鎂治療慢性乙型肝炎的臨床觀察[A];中華醫(yī)學(xué)會(huì)全國第九次感染病學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2006年
5 吳建明;;異甘草酸鎂注射液治療慢性乙型肝炎療效觀察[A];2012年浙江省醫(yī)學(xué)會(huì)肝病、感染病學(xué)學(xué)術(shù)年會(huì)暨浙江省感染科醫(yī)師學(xué)術(shù)年會(huì)論文集[C];2012年
6 許青田;;異甘草酸鎂治療慢性乙型肝炎臨床觀察[A];中華醫(yī)學(xué)會(huì)全國第九次感染病學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2006年
7 林潔;吳明釵;林暉;李銘銘;;異甘草酸鎂與3種含果糖輸液配伍的穩(wěn)定性研究[A];2012年浙江省醫(yī)學(xué)會(huì)臨床藥學(xué)學(xué)術(shù)年會(huì)暨醫(yī)院藥事管理質(zhì)控中心、臨床藥學(xué)分會(huì)十周年慶典大會(huì)論文集[C];2012年
8 徐建國;胡晉紅;;異甘草酸鎂治療皮炎藥效學(xué)研究[A];藥學(xué)發(fā)展前沿論壇及藥理學(xué)博士論壇論文集[C];2008年
9 馮建德;;苦參堿聯(lián)合異甘草酸鎂治療病毒性肝炎重度黃疸的療效觀察[A];全國中西醫(yī)結(jié)合肝病新進(jìn)展講習(xí)班、江西省第二次中西醫(yī)結(jié)合肝病學(xué)術(shù)會(huì)議資料匯編[C];2010年
10 熊德琴;謝南;敖琴芳;;異甘草酸鎂聯(lián)合丹參對(duì)慢性乙型肝炎患者肝功能和肝纖維化指標(biāo)的影響[A];江西省中西醫(yī)結(jié)合學(xué)會(huì)傳染病專業(yè)委員會(huì)成立大會(huì)暨首屆江西省中西醫(yī)結(jié)合傳染病學(xué)術(shù)會(huì)議論文匯編[C];2011年
相關(guān)重要報(bào)紙文章 前4條
1 通訊員 張維偉 宋玉冰 記者 孫鐵軍;6項(xiàng)成果達(dá)國際先進(jìn)[N];連云港日?qǐng)?bào);2008年
2 趙明;植物肝藥“異甘草酸鎂”將上市[N];醫(yī)藥養(yǎng)生保健報(bào);2005年
3 張杰、王強(qiáng);保肝創(chuàng)新藥異甘草酸鎂獲批[N];中國醫(yī)藥報(bào);2005年
4 劉燕玲;我國已成甘草研發(fā)領(lǐng)跑者[N];健康報(bào);2006年
相關(guān)碩士學(xué)位論文 前10條
1 洪金鵬;異甘草酸鎂護(hù)肝作用的實(shí)驗(yàn)研究及臨床觀察[D];蘭州大學(xué);2015年
2 董方圓;異甘草酸鎂在胃癌中的抗炎抗腫瘤作用及其機(jī)制的初步研究[D];第二軍醫(yī)大學(xué);2015年
3 莊孝峰;異甘草酸鎂對(duì)急性肝衰竭小鼠FGL2凝血酶原酶和血小板活化因子表達(dá)的影響[D];南昌大學(xué)醫(yī)學(xué)院;2015年
4 郭曼;異甘草酸鎂對(duì)奧沙利鉑抗腫瘤作用的影響[D];青島大學(xué);2015年
5 賀云霞;異甘草酸鎂預(yù)防放射性肝損傷的研究[D];延安大學(xué);2016年
6 劉慧嬌;新加八味降酶湯聯(lián)合異甘草酸鎂治療藥物性肝損傷臨床療效觀察[D];南京中醫(yī)藥大學(xué);2017年
7 劉瑩;異甘草酸鎂預(yù)防癌性貧血的實(shí)驗(yàn)研究[D];第二軍醫(yī)大學(xué);2014年
8 金娟;異甘草酸鎂對(duì)實(shí)驗(yàn)性肝損傷模型的影響及其機(jī)制研究[D];安徽醫(yī)科大學(xué);2010年
9 李興;異甘草酸鎂對(duì)膽道梗阻致肝損傷肝功能保護(hù)作用的動(dòng)物實(shí)驗(yàn)研究[D];第二軍醫(yī)大學(xué);2014年
10 徐建國;異甘草酸鎂抗皮炎濕疹藥效學(xué)及其抗炎機(jī)制研究[D];第二軍醫(yī)大學(xué);2010年
，本文編號(hào)：2303460
本文鏈接：http://sikaile.net/yixuelunwen/xiaohjib/2303460.html
